

PhotoCure ASA

Results 2nd quarter 2002

August 2002



Highlights


- Metvix[®]
 - Commercialisation on track
 - Positive clinical data in treatment of nodular BCC achieved in US
- Hexvix[®]
 - On track for filing of marketing authorisation first half 2003
- Benzvix[®]
 - Clinical pilot studies on track
- Alpharadin[™]
 - PhotoCure has acquired shares and share options in Anticancer Therapeutics Inventions
- Strong financial position




Marketing Metvix®

–Commercialisation in the Nordic area on track

Clinics with PhotoCure lamps



Number of light sources



Marketing Metvix[®]

–Commercialisation in Sweden

- Regulatory approval June 2001
- Reimbursed price of 1300 SEK per tube of Metvix[®] October 2001
- Procedure fee negotiations ongoing
- Target group: 120 dermatology centres
- Training personnel from 78 centres
 - 46 centres completed
 - 32 centres to be trained
- Provided 45 centres with 65 light sources
 - Placement of light sources started in January 2002



Marketing Metvix[®]

–Commercialisation in Norway

- National approval February 2002
- Approved price of 1100 NOK per tube of Metvix[®]
- Reimbursement application filed for Metvix[®]
- Target group: 85 dermatology centres
- Provided 34 centres with 50 light sources
- Training of centres ongoing



Marketing Metvix[®]

–Commercialisation in Denmark

- Metvix[®] commercially available July 2002
- Single patient reimbursement available
- Procedure fee negotiations ongoing
- Metvix[®] priced at 1100 DKK per tube
- Target group: 90 dermatology centres
- Market introduction symposium held in May
- Training of centres ongoing
 - 50 centres booked for training courses



Marketing Metvix[®]

–Commercialisation in Finland

- National approval May 2002
- Target group: 100 dermatology centres
 - 5 University hospitals established
- Reimbursement application filed for Metvix[®]
- Metvix[®] priced at 148 Euro per tube
- Market introduction symposium held in May
- Training of centres ongoing
- Focus on hospitals and opinion leaders



Metvix®

– Marketing Authorisations in several countries


- National authorisations issued in:
 - Sweden, Norway, Denmark, Finland, Iceland, Germany, UK, Ireland, Luxembourg, Greece, New Zealand
- Awaiting national authorisations in:
 - Belgium, Austria, Spain, Italy
- Application pending in Switzerland, USA and Australia
- Galderma
 - Preparing new applications in several countries



Metvix®

– Strong clinical data achieved in USA

Nodular BCC complete response rate



Lesion area and a margin fully examined under microscope



Marketing Metvix®

– Galderma pre-launch preparations ongoing

- Several meetings held between Galderma and PhotoCure executives on three continents
- Several Steering Committee meetings held
- Galderma hired dedicated management resources
- Galderma task force established
 - More resources allocated than for any other product
 - Fastest progress ever since signing
- PhotoCure employee present at Galderma headquarter
- Transfer of marketing authorisation licenses to Galderma
- Metvix® PDT actively promoted at the World Congress of Dermatology in Paris



New indications in dermatology

– Several possible indications

- Positive data on acne
 - Pilot study completed
 - World wide acne market totals 1.7 bn USD per year
- Other areas of interest
 - Photoaging (skin rejuvenation)
 - Transplant patients
 - Wound healing (pilot study planned)
 - Viral diseases



Hexvix® preparation

Hexyl aminolevulinate powder

+

Phosphate buffer saline 50 mL

➤

Hexvix® solution

- Instilled 1 hour in the bladder
- Start cystoscopy within 30 minutes



Hexvix[®] in bladder cancer

– positive results in phase II clinical trial

Four times more patients with CIS lesions detected

(CIS = Carcinoma in Situ)

Hexvix [®]		White light	
12 / 13	92%	3 / 13	23%

Patients have one or more CIS lesions



Hexvix[®]

– phase III program ongoing

■ Europe

- Enrolment in first clinical phase III study completed
 - Interim data confirm the positive phase II results
- One additional study initiated

■ USA

- Investigational New Drug status obtained
- Phase III studies initiated

■ First marketing application planned 1st half 2003

- Preparations ongoing



Hexvix[®]

– pre-marketing activities ongoing

- Contract manufacturer selected
- Market research study completed
- Price and reimbursement preparations ongoing
- Out-licensing activities initiated
 - PhotoCure will at least retain the Nordic region



Research and development – strong pipeline

ALA derivatives R&D opportunities

(excluding dermatology and urology)

- Barrets oesophagus – clinical pilot study initiated
- Colo-rectal cancer – clinical pilot study initiated
- Lesions in mouth, pharynx and larynx
- Gynaecology (vulva, cervix, ovarian)
- Brain tumours
- Mammary tumours (breast conserving surgery)



Research and development

– Alpharadin™ for bone metastasis

- Alpharadin™ is being developed by Anticancer Therapeutic Inventions AS (ATI)
 - PhotoCure owns 6.6% of ATI
 - Share options to increase ownership to more than 60%
- Alpharadin™
 - A bone metastasis-seeking radio pharmaceutical
 - A new concept based on alpha particles
 - Phase I study ongoing



PhotoCure

– important milestones the next twelve months

As of May 2002

Metvix®

- Expand the number of clinics in the Nordic countries
 - 150 clinics with light sources
- Submit additional clinical data in Australia, France, Portugal & Holland
- File new drug application for BCC in the US
- Initiate clinical study for new indication
- Launches by Galderma in up to 10 countries outside the Nordic region



PhotoCure

– important milestones the next twelve months

As of May 2002

Hexvix®

- Complete current ongoing phase III studies for bladder cancer detection
- File first marketing authorisation application for bladder cancer detection
- Start clinical pilot study on treatment of bladder cancer

Benzvix®

- Complete current ongoing clinical pilot studies

PCI Biotech AS

- First product on the research market
- First clinical pilot study started



Financial Statements

– Profit & Loss

Three months ended		All figures in NOK 1,000	Six months ended	
30.06.2002	30.06.2001		30.06.2002	30.06.2001
4 594	529	Sales	8 291	931
6	2 061	Other revenues	130	2 686
4 601	2 590	Total operating revenues	8 422	3 617
1 028	5 545	Salaries & other pers. costs	4 874	10 640
21 821	14 731	External R&D costs	45 356	27 551
312	182	Ordinary depreciation	545	341
10 884	6 712	Other operating expenses	19 855	11 205
34 045	27 170	Total operating expenses	70 630	49 738
-29 444	-24 580	Operating income	-62 208	-46 121
2 276	6 204	Net financial income	5 529	13 301
-27 169	-18 376	Loss before tax	-56 678	-32 820
-	-	Tax	-	-
-27 169	-18 376	Net loss for the period	-56 678	-32 820
-235	-96	Of this minority interests	-548	-102
-1.56	-1.07	Net loss per share (NOK)	-3.26	-1.91



Financial statements

- Balance sheet

Figures in NOK 1,000	30.06.2002	31.12.2001
Fixed assets	11 413	3 935
Receivables	24 181	10 456
Securities	221 229	283 564
Cash and bank deposits	83 930	21 614
Total assets	340 752	319 569
Shareholders' equity	206 212	259 398
Long term liabilities	17 524	17 362
Current liabilities	117 016	42 809
Total shareholders' capital & liabilities	340 752	319 569

